Prevalence and mortality of lung comorbidities among patients with COVID-19: A systematic review and meta-analysis.
Prevalence and mortality of lung comorbidities among patients with COVID-19: A systematic review and meta-analysis.
复制标题
DOI：
10.4103/lungindia.lungindia_497_20
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Alsalamah JA
中科院分区：
文献类型：
--
作者：
Alkhathami MG;Advani SM;Abalkhail AA;Alkhathami FM;Alshehri MK;Albeashy EE;Alsalamah JA
COVID-19感染见于所有年龄组，但已显示老年人和有潜在合并症的人更易感染。患有严重COVID-19感染和合并症的患者更容易出现呼吸窘迫综合征，使用机械呼吸机，并最终死于这些并发症。几乎没有证据表明COVID-19患者中潜在肺部合并症的患病率和相关死亡率。我们对PubMed（Medline）、Embase（奥维德）、Google Scholar和科克伦图书馆等文献进行了系统综述。我们最后一次搜索的日期是2020年4月29日。我们纳入了所有关于COVID-19的原创研究文章，并使用随机效应模型计算了COVID-19患者中慢性肺部疾病患者的患病率。此外，我们评估了与这些肺部合并症相关的COVID-19患者的死亡率。作者确定了29篇报道COVID-19患者中慢性肺部疾病患病率的文章。其中，26人来自中国，3人来自美国。包括哮喘、慢性阻塞性肺疾病（COPD）和肺癌在内的肺部合并症的合并患病率分别为3%（95%置信区间[CI] = 0%-14%）、2.2%（95% CI = 0.02%-0.03%）和2.1%（95% CI = 0.00%-0.21%）。与这些合并症相关的死亡率分别为COPD 30%（41/137）和肺癌19%（7/37）。未报告哮喘患者的死亡率。这项研究提供了COVID-19患者慢性肺部疾病患病率的最新证据。哮喘，其次是COPD和肺癌，是与COVID-19相关的最常见的肺部合并症，而COPD的死亡率更高。未来的研究需要评估诊断为COVID-19的患者的其他肺部合并症和相关死亡率。
COVID-19 infections are seen across all age groups, but they have shown to have a predisposition for the elderly and those with underlying comorbidities. Patients with severe COVID-19 infections and comorbidities are more prone to respiratory distress syndrome, mechanical ventilator use, and ultimately succumb to these complications. Little evidence exists of the prevalence of underlying lung comorbidities among COVID-19 patients and associated mortality. We performed a systematic review of the literature including PubMed (Medline), Embase (Ovid), Google Scholar, and Cochrane Library. The last date for our search was April 29, 2020. We included all original research articles on COVID-19 and calculated prevalence of chronic lung disease patients among COVID-19 patients using random effects model. Further, we assessed for mortality rates among COVID-19 patients associated with these lung comorbidities. The authors identified 29 articles that reported prevalence of chronic lung conditions among COVID-19 patients. Among those, 26 were from China and 3 from the United States. The pooled prevalence of lung comorbidities including asthma, chronic obstructive pulmonary disease (COPD), and lung cancer was 3% (95% confidence interval [CI] = 0%–14%), 2.2% (95% CI = 0.02%–0.03%), and 2.1% (95% CI = 0.00%–0.21%), respectively. Mortality rates associated with these comorbidities was 30% (41/137) for COPD and 19% (7/37) for lung cancer respectively. No mortality rates were reported for patients with asthma. This study offers latest evidence of prevalence of chronic lung conditions among patients with COVID-19. Asthma, followed by COPD and lung cancer, was the most common lung comorbidity associated with COVID-19, while the higher mortality rate was found in COPD. Future studies are needed to assess other lung comorbidities and associated mortality among patients diagnosed with COVID-19.
登录
查看更多内容
影响因子：
6.1
作者：
Liu, Kui;Fang, Yuan-Yuan;Liu, Hui-Guo
通讯作者：
Liu, Hui-Guo
影响因子：
3.7
作者：
Duval, S;Tweedie, R
通讯作者：
Tweedie, R
影响因子：
12
作者：
Huang, Yihui;Tu, Mengqi;Guo, Liang
通讯作者：
Guo, Liang
影响因子：
82.9
作者：
Kuba K;Imai Y;Rao S;Gao H;Guo F;Guan B;Huan Y;Yang P;Zhang Y;Deng W;Bao L;Zhang B;Liu G;Wang Z;Chappell M;Liu Y;Zheng D;Leibbrandt A;Wada T;Slutsky AS;Liu D;Qin C;Jiang C;Penninger JM
通讯作者：
Penninger JM
影响因子：
64.8
作者：
Imai Y;Kuba K;Rao S;Huan Y;Guo F;Guan B;Yang P;Sarao R;Wada T;Leong-Poi H;Crackower MA;Fukamizu A;Hui CC;Hein L;Uhlig S;Slutsky AS;Jiang C;Penninger JM
通讯作者：
Penninger JM